Learn when hypertrophic cardiomyopathy becomes severe and how a cardiologist guides you through heart transplant evaluation ...

Mavacamten, the first-in-class cardiac myosin inhibitor approved for treatment of symptomatic adults with obstructive HCM, is efficacious for adolescents.

Adolescent patients with obstructive hypertrophic cardiomyopathy (HCM) who received the drug mavacamten saw a significant ...

The cardiac myosin inhibitor gets a big win in the SCOUT-HCM trial ...

A global clinical trial involving The Hospital for Sick Children (SickKids) has found that mavacamten—a heart medication ...

Researchers at Children's Hospital of Philadelphia (CHOP) reported today that adolescents with hypertrophic cardiomyopathy (HCM) who took mavacamten experienced reduced obstruction, allowing blood to ...

Please provide your email address to receive an email when new articles are posted on . Hypertrophic cardiomyopathy is the most common monogenic CV disorder, yet perhaps the most frequently ...

Treatment with aficamten significantly improved exercise capacity compared with placebo. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for aficamten for ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Carolyn Ho, MD: ...

"Older patients often tolerate medications poorly and younger patients may feel lethargic and tired with beta blockers and calcium channel blockers. These patients would be appropriate candidates for ...

The physical symptoms of obstructive hypertrophic cardiomyopathy (HCM) are very real, ranging from chest pain and shortness of breath to a racing heart, lightheadedness, and fatigue. But there’s also ...

The Emotional Impact of Obstructive HCM Practical Coping Strategies to Try Integrate Emotional Health Into Daily Life The physical symptoms of obstructive hypertrophic cardiomyopathy (HCM) are very ...